Although current tau-related biomarkers—such as plasma and cerebrospinal fluid tau—lack disease specificity, they may hold diagnostic and mechanistic value in PSP (Giannakis et al., 2025). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.